| First Author | Hoa N | Year | 2018 |
| Journal | Mol Cell Endocrinol | Volume | 470 |
| Pages | 240-250 | PubMed ID | 29127073 |
| Mgi Jnum | J:263341 | Mgi Id | MGI:6163885 |
| Doi | 10.1016/j.mce.2017.11.004 | Citation | Hoa N, et al. (2018) Estrogen receptor beta maintains expression of KLF15 to prevent cardiac myocyte hypertrophy in female rodents. Mol Cell Endocrinol 470:240-250 |
| abstractText | Maintaining a healthy, anti-hypertrophic state in the heart prevents progression to cardiac failure. In humans, angiotensin II (AngII) indirectly and directly stimulates hypertrophy and progression, while estrogens acting through estrogen receptor beta (ERbeta) inhibit these AngII actions. The KLF15 transcription factor has been purported to provide anti-hypertrophic action. In cultured neonatal rat cardiomyocytes, we found AngII inhibited KLF1 expression and nuclear localization, substantially prevented by estradiol (E2) or beta-LGND2 (beta-LGND2), an ERbeta agonist. AngII stimulation of transforming growth factor beta expression in the myocytes activated p38alpha kinase via TAK1 kinase, inhibiting KLF15 expression. All was comparably reduced by E2 or beta-LGND2. Knockdown of KLF15 in the myocytes induced myocyte hypertrophy and limited the anti-hypertrophic actions of E2 and beta-LGND2. Key aspects were confirmed in an in-vivo model of cardiac hypertrophy. Our findings define additional anti-hypertrophic effects of ERbeta supporting testing specific receptor agonists in humans to prevent progression of cardiac disease. |
